Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03370861 · ClinicalTrials.gov registry record
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
A clinical trial, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- 54
- Enrollment target
NCT03370861: Clinical Trial study, sponsored by Washington University School of Medicine.
NCT03370861 is a clinical trial that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03370861 was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- 54 participants
- Enrollment target
Study Summary
The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy.
Primary Outcome
Electronic medical records will be queried for specific drug-related adverse events known as immune-related Adverse Events (irAEs) including but not limited to colitis, hypophysitis, hepatitis, pneumonitis, pancreatitis, arthritis, rash, and vitiligo.
Interventions
- BIOLOGICAL Immunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-11-08 |
| Est. Completion | 2022-12-31 |
Why NCT03370861 stopped before completion
NCT03370861 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Immunotherapy is the first listed.
NCT03370861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03370861 about?
NCT03370861 is a clinical study titled "How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes". The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy.
What is the current status of trial NCT03370861?
This trial is currently terminated. The enrollment target is 54 participants. The study started on 2017-11-08. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03370861?
The interventions under investigation include: Immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT03370861?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI